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Abstract
Purpose: A recent large genome-wide association study (GWAS) identified multiple variants associated with primary angle-
closure glaucoma (PACG). The present study investigated the role of these variants in two cohorts with PACG recruited from
Australia and Nepal.
Method: Patients with PACG and appropriate controls were recruited from eye clinics in Australia (n = 232 cases and n= 288
controls) and Nepal (n = 106 cases and 204 controls). Single nucleotide polymorphisms (SNPs) rs3753841 (COL11A1),
rs1015213 (located between PCMTD1 and ST18), rs11024102 (PLEKHA7), and rs3788317 (TXNRD2) were selected and
genotyped on the Sequenom. Analyses were conducted using PLINK and METAL.
Results: After adjustment for age and sex, SNP rs3753841 was found to be significantly associated with PACG in the
Australian cohort (p = 0.017; OR = 1.34). SNPs rs1015213 (p = 0.014; OR 2.35) and rs11024102 (p = 0.039; OR 1.43) were
significantly associated with the disease development in the Nepalese cohort. None of these SNPs survived Bonferroni
correction (p = 0.05/4 = 0.013). However, in the combined analysis, of both cohorts, rs3753841 and rs1015213 showed
significant association with p-values of 0.009 and 0.004, respectively both surviving Bonferroni correction. SNP rs11024102
showed suggestive association with PACG (p-value 0.035) and no association was found with rs3788317.
Conclusion: The present results support the initial GWAS findings, and confirm the SNP’s contribution to PACG. This is the
first study to investigate these loci in both Australian Caucasian and Nepalese populations.
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Introduction
Primary angle-closure glaucoma (PACG) is a subtype of
glaucoma characterised by obstruction of the irido-corneal angle,
increase in the intraocular pressure, and slow progressive
destruction of the optic nerve with corresponding loss of the
peripheral visual field. [1] Glaucoma is the leading cause of
irreversible blindness worldwide, with primary angle-closure
glaucoma accounting for almost half of all blind glaucoma
patients. [2] The number of patients with PACG is expected to
rise by approximately 5 million people from 16 million over the
next decade. [1].
Interestingly, affected individuals tend to exhibit a consistent
spectrum of anatomical biometric features such as reduced
anterior chamber depth along with narrowing in the irido-corneal
drainage, increased lens thickness and change in its position,
hyperopic refractive error, and short axial length. [3] The disease
is more prevalent in older age groups, in females, and in certain
populations including Eskimos and Asians. [4].
Primary angle-closure glaucoma is a complex heterogeneous
disease, with the genetic susceptibility under investigation.
Recently, a two staged genome wide association study (GWAS)
was conducted on a large cohort with PACG (3,771 cases and
18,551 controls) from multiple ethnicities. Three susceptibility loci
were detected at genome-wide significance on meta-analysis of all
data from both stages; PLEKHA7 rs11024102, COL11A1
rs3753841, and rs1015213 located between PCMTD1 and ST18.
[5].
PLEKHA7 (pleckstrin homology domain-containing family A
member 7) located on Chromosome 11, is an adherens junction
protein [6]. Adherens junction (AJ) are required for organization
of the epithelial architecture [7], and contribute to tissue
homoeostasis. [8] It is likely to be involved in affecting the fluid
flow across the inner wall of Schlemm’s canal. [9] It was proposed
that mutation in PLEKHA7 could affect the fluid dynamics in the
pathophysiology of angle-closure glaucoma. [10].
COL11A1 encodes one of the two alpha chains of type Xl
collagen. It is associated with type II Stickler and Marshall
syndromes [11–13] which are congenital conditions that include
high myopia and blindness from retinal detachment. [14] The
GWAS data showed a single SNP, rs3753841, to be associated
with PACG, and the authors proposed the causal variants
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predisposing towards PACG within COL11A1 may alter its gene
expression such as to engineer a reverse effect to that observed in
myopic eyes.
The third locus, rs1015213, is located on chromosome 8
between two genes, PCMTD1 and ST18, but as the associated was
found to be in LD with PCMTD1, it was suggested as the most
likely candidate gene. PCMTD1 encodes protein-L-isoaspartate O-
methyltransferase domain-containing protein 1. Very little is
known about the function of this gene, but it is expressed in eye
tissues including iris and trabecular meshwork which are involved
in the pathogenesis of PACG. PLEKHA7 and COL11A1 are also
found to be expressed in most eye tissues, especially in iris and
trabecular meshwork.
The GWAS study reported a fourth locus rs3788317 that did
not reach the level of genome wide significance in the meta-
analysis. It is located in an intron of the TXNRD2 (thioredoxin
reductase 2) gene on chromosome 22. Thioredoxin reductase has
been recently found in the lens and is reported to participate in the
repair process of oxidative damaged lens proteins/enzymes in
patients with cataracts. [15] The variations within this gene may
participate in the pathogenesis of PACG, since one of the clinical
risk factors of PACG is change in thickness and position of the
lens.
The present study aimed to investigate the replication of these
SNPs in our PACG cohort recruited from two populations from
Australia and Nepal.
Materials and Methods
Approval was obtained from the human research ethics
committee of the Southern Adelaide Health Service and Flinders
University, and the Institutional Review Committee of the
Tilganga Institute of Ophthalmology. This study has been
conducted in accordance with the Declaration of Helsinki and
Figure 1. Plot showing the study power of the selected SNPs in both (A) Australian (n=232 cases and n=288 controls) and (B)
Nepalese (n=106 cases and 204 controls) populations per-allele odds ratio. X-axis represents relative risk (range from 1.0 to 2.4) and Y-axis
the power in percentage. Minor allele frequencies of each SNP are presented in Table 1.
doi:10.1371/journal.pone.0067903.g001
Genetics of Angle Closure Glaucoma
PLOS ONE | www.plosone.org 2 June 2013 | Volume 8 | Issue 6 | e67903
its subsequent revisions. Written informed consent was obtained
from each individual.
Australian Caucasian participants were recruited from Oph-
thalmology clinics in Australia through the Australian and New
Zealand Registry of Advanced Glaucoma ANZRAG. [16] All
participants reported in this study were Caucasian. The Nepalese
cohort was recruited from the Nepal Glaucoma Eye Clinic,
Tilganga Institute of Ophthalmology, Kathmandu Nepal by one
of the authors (S.S.T). [17,18].
Each participant underwent a complete eye examination
including; slit lamp examination of the anterior chamber,
gonioscopy, best corrected visual acuity, measurement of intraoc-
ular pressure, fundus examination with special attention to optic
disc parameters, and visual field assessment. Refraction was
carried out using a streak retinoscope (Beta 200, Heine, Germany),
followed by a subjective refraction. [17].
232 Australian and 106 Nepalese participants identified with
PACG were recruited. Patients with primary angle-closure
glaucoma were included using the definition of the International
Society of Geographical and Epidemiological Ophthalmology
(ISGEO) described by Foster and colleagues. [19] It was based on
the presence of glaucomatous optic neuropathy with cup:disc
ratio$0.7, intraocular pressure greater than 21 mmHg, peripheral
visual loss, presence of at least 180 degrees of closed angle in which
the trabecular meshwork is not visible on gonioscopy.
Controls were required to have none of the above character-
istics, and no family history of glaucoma or previous surgery for
glaucoma. Participants with pseudophakia or secondary angle-
closure glaucoma caused by events such as uveitis, trauma or lens
subluxation were excluded. The control group consisted of 288
Australian and 204 Nepalese individuals. The Australian cohort
was ascertained from retirement villages in Adelaide, South
Australia. Nepalese controls were participants in a population-
based study of Kathmandu, Nepal. Control individuals were
chosen specifically to be matched for gender and ethnic group to
the Nepalese cases. Controls from both cohorts were slightly older
than cases by design for this aging disease.
Genomic DNA was extracted from peripheral whole blood
using the QiaAmp Blood Midi (Nepalese samples) or Maxi
(Australian samples) Kit (Qiagen, Valencia, California). SNPs were
selected from the literature; rs3753841 (COL11A1_
NM_080630.3), rs1015213 (located between PCMTD1 and
ST18), rs11024102 (PLEKHA7 NM_175058.4), and rs3788317
(TXNRD2 NM_006440.3). [10] Genotyping was conducted using
the iPLEX Gold chemistry (Sequenom Inc, San Diego, California)
on an Autoflex mass spectrometer (Sequenom Inc, San Diego,
California) at the Australia Genome Research Facility (AGRF),
Brisbane.
Power calculations were conducted in each cohort to assess the
power of the study to detect association at the four tested SNPs
across a range of effect sizes from 1.0 to 2.4, using the minor allele
frequency observed for each SNP in each cohort in this study.
[20].
Association analyses were conducted using PLINK. [21]. Each
cohort was analysed separately withadjustment for sex and age
under an additive model using multivariate logistic regression.
Combined analyses were conducted using the Cochran-Mantel-
Haenszel 2626K test (cmh) performed to allow for differences
between the populations. The differences in the odds ratios
between the results of the current study and previously reported
results were viewed in Forest Plot Viewer v1.00 which generates
forest plots from odds ratio and confidence interval inputs. [22].
Meta-analysis of the two cohorts was conducted using the age
and sex adjusted results, using logistic regression and inverse
variance weights to calculate an overall z-statistics and p-value
with the METAL program. [23].
Table 1. Minor allele frequencies (%) of SNPs, and p-value adjusted for age and sex for the Australian and Nepalese cohorts with
the odds ratio (95% CI).
Australian Nepalese
SNP Minor Allele
MAF
Case
MAF
Control p-value OR (95% CI)
MAF
Case
MAF
Control p-value OR(95%CI)
rs3753841 G 0.43 0.36 0.017 1.34 (1.1–1.7) 0.35 0.31 0.308 1.20 (0.7–1.3)
rs1015213 A 0.12 0.09 0.157 1.41 (0.9–2.0) 0.10 0.05 0.014 2.35 (1.3–3.8)
rs11024102 G 0.31 0.29 0.411 1.10 (0.9–1.4) 0.50 0.41 0.039 1.43 (1.0–1.6)
rs3788317 A 0.22 0.22 0.75 1.03 (0.8–1.3) 0.16 0.17 0.742 0.92 (0.5–1.0)
P-value of less than 0.013 is considered significant. OR =Odds ratio, MAF=minor allele frequency.
doi:10.1371/journal.pone.0067903.t001
Table 2. Association results of previously reported PACG SNPs after adjustment for population stratification under a Cocrhan-
Mantel-Haenszel test, showing p-value under the additive model, meta-analysis using the adjusted odds ratio and standard error of
the point estimate, accompanied by p-het and I-squared index.
SNP Minor allele MAF Cases MAF Control p-CMH OR (95% CI) p-meta I2 p-het
rs3753841 G 0.35 0.33 0.009 1.31 (1.1–1.6) 0.011 0% 0.62
rs1015213 A 0.08 0.06 0.004 1.61 (1.1–2.3) 0.011 35.1% 0.21
rs11024102 G 0.36 0.36 0.035 1.25 (1.0–1.5) 0.067 35.1% 0.21
rs3788317 A 0.20 0.21 0.999 0.99 (0.8–1.3) 0.936 0% 0.65
P-value ,0.013 is considered significant. MAF: minor allele frequency, I2: measures heterogeneity, p-het: p-value for heterogeneity.
doi:10.1371/journal.pone.0067903.t002
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Results
Replication of reported PACG associated SNPs was investigated
using independent cohorts with PACG from Australia and Nepal.
We genotyped the top ranked SNPs from the previous reported
GWAS study; rs3753841 (COL11A1), rs1015213 (located between
PCMTD1 and ST18), rs11024102 (PLEKHA7), and rs3788317
(TXNRD2).
Power calculations were undertaken to determine if the current
cohorts were sufficiently powered to detect genetic association with
the disease at a=0.05 level assuming complete linkage disequi-
librium between the disease causing variant and the marker, in
both cohorts. The overall prevalence of PACG is estimated to be
0.4% in European derived populations [24] and 0.43% in
Nepalese population. [25] The power varies between SNPs and
cohorts due to differences in the allele frequencies in each
population and the size of each cohort. The Australian cohort has
80% power to detect an association at least as big as that
previously reported at all SNPs except rs1015213. The Nepalese
cohort can detect associations with confidence at both SNPs
rs3753841 and rs11024102 (Figure 1).
The allele frequencies and associations were evaluated in each
cohort independently with age and sex adjustment as shown in
Table 1. In the Australian cohort, rs3753841 (COL11A1) was
associated under the additive model (p = 0.017, OR 1.34; 95% CI
1.1 to 1.7). No association was observed in the Nepalese cohort for
this SNP. Conversely, both rs1015213 (located between PCMTD1
and ST18) and rs11024102 (PLEKHA7) were found to be
significantly associated with PACG in the Nepalese cohort
(p = 0.014 and p=0.039, respectively). After applying Bonferroni
correction for multiple testing in the population-specific analysis
none of these SNPs showed significance.
The combined analysis (Table 2) using the Cochran-Mantel-
Haenszel test, unadjusted for covariates, showed three SNPs to be
significantly associated with PACG; rs3753841 with p-value of
0.009 (OR 1.31), rs1015213 with p-value of 0.004 (OR 1.61), and
rs11024102 with p-value 0.035 (OR 1.25). After applying
correction for multiple testing (Bonferroni), both rs3753841 and
rs1015213 remained significant. When the meta-analysis was
conducted using sex and age adjusted results, both rs3753841 (p-
value = 0.011) and rs1015213 (p-value = 0.011) were significantly
associated with the disease. By assessing the I2 index that measures
the extent of heterogeneity between sample collections in the
meta-analysis (,25% indicates low heterogeneity, 25%,I2,50%
moderate heterogeneity, and .50% high heterogeneity), SNPs
rs11024102 and rs1015213 had moderate heterogeneity (), which
was not significant (Table 2). SNPs rs3753841 and rs3788317
showed no heterogeneity (Table 2).
The differences in the effect size of Australian, Nepalese,
combined cohorts and the results from previous GWAS are
presented in Figure 2, showing that the direction of association of
these three SNPs is the same as the previous GWAS report. SNP
rs3788317 did not reveal a statistically significant association with
PACG in any analysis.
Figure 2. Forest plot showing the odds ratio and 95% CI of the four typed SNPs in the Australian, the Nepalese, the combined
analysis and the meta-analysis results of previous GWAS. The risk estimate axis ranges from 0.5 to 4.0.
doi:10.1371/journal.pone.0067903.g002
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Discussion
The molecular mechanisms leading to PACG are poorly
understood. In this study we sought to replicate the top ranked
SNPs from a recent GWAS of predominantly Asian patients. Our
results support the association of three loci (rs3753841, rs1015213,
and 11024102) in our cohorts, and demonstrate that carriers of the
minor alleles of these SNPs are approximately 1.5 times more
likely to develop PACG. The effect size in our Australian cohort is
similar to the findings reported in the small UK cohort included in
the initial GWAS study.
SNP rs3753841 is located in the COL11A1 gene (OMIM
120280). It is a missense mutation, situated in a coding region of
the gene g.199135C.T (p.Pro1284Leu). The previous GWAS
showed the minor allele to be the risk with meta-analysis p-value of
9.22610210 (OR 1.20). The variant is predicted to be benign and
tolerated by PolyPhen2 or SIFT, respectively. This suggests that
this variant is unlikely to be the causative allele despite being a
non-synonymous change, but it is likely tagging another functional
variant that is responsible for this disease.
SNPs rs11024102, and rs3788317 are situated in an intron of
the PLEKHA7 (OMIM: 612686) and TXNRD2 (OMIM: 606448)
genes respectively. SNP rs11024102 met the criteria for genome
wide significance in the GWAS (meta-analysis p-value of
5.33610212, OR 1.22). Our study shows a suggestive association
of this SNP. Although it did not reach statistical significance, our
finding supports the previous GWAS result. In addition,
rs3788317 did not reach genome wide significance in the reported
GWAS with meta-analysis p-value of 1.7361027 (OR 0.82), and it
also failed to show association in our study. The inconsistency in
the direction of this SNP within our study cohorts and with the
previous GWAS study makes rs3788317 unlikely to be a true
PACG SNP. We also report that the SNP rs1015213 showed
replication in our cohorts. Although both rs11024102 and
rs1015213 show a moderate degree of heterogeneity, this was
not significant and thus does not affect the conclusions.
The main limitation of this study is the small sample size.
However, the effect sizes are in the same direction as previously
reported. We considered the cohort underpowered to detect
association at rs1015213, however, the observed odds ratio was
greater than expected and a significant result was detected at this
SNP as well as at the more common SNPs. It is now necessary to
investigate how the candidate genes at each of these loci affect the
pathogenicity of this blinding disease. In conclusion, this is the first
study to replicate findings from a recent genome-wide study, and
further confirms the role of PLEKHA7 and COL11A1 as candidate
genes for PACG. Further analysis is also required to identify how
rs1015213 contributes to the disease.
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